Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Cited by (1,004)

Items 401–500 of 1,004

1. Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment
   Stefano Ciardullo, Michela Vergani, Gianluca Perseghin · 2023 · Journal of Clinical Medicine
2. Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
   Sudha S. Shankar, Samuel Joseph Daniels, Darren C. Robertson, Janeli Sarv, José Sánchez, Debra Carter, Lutz Jermutus, Benjamin Challis, Arun Jayant Sanyal · 2024 · Clinical Gastroenterology and Hepatology
3. Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview
   Wei Xiong Wen, Siang Yin Lee, Rafaella Siang, Rhun Yian Koh · 2017 · Advances in Therapy
4. Imaging of nonalcoholic fatty liver disease and its clinical utility
   Evangelos Chartampilas · 2018 · HORMONES
5. Relationship between three commonly used non‐invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non‐alcoholic steatohepatitis
   Naga Chalasani, Manal F. Abdelmalek, Rohit Seth Loomba, Kris V. Kowdley, Arthur J. McCullough, Srinivasan Dasarathy, Brent A. Neuschwander‐Tetri, Norah A. Terrault, Beatrice Ferguson, Reshma Shringarpure et al. · 2018 · Liver International
6. MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease
   Jiaofeng Huang, Weijie Ou, Ming-Fang Wang, Medha Singh, Yuxiu Liu, Shiying Liu, Yinlian Wu, Yueyong Zhu, Rahul Kumar, Su Lin · 2021 · Risk Management and Healthcare Policy
7. The therapeutic landscape of hepatocellular carcinoma
   Suchira Gallage, Maria Garcia Beccaria, Marta Szydlowska, Mohammad Rahbari, Raphael U. Mohr, Frank Tacke, Mathias F Heikenwälder · 2021 · Med
8. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus
   Vincent Olivier Mallet, Lucia Parlati, Alessandro Martinino, Juan Pablo Scarano Pereira, Carmen Navas Jiménez, Mehdi Sakka, Samir Bouam, Aurélia RETBI, Donika Krasteva, Jean–François Méritet et al. · 2021 · Journal of Hepatology
9. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study
   Neeta B. Amin, Amanda Darekar, Quentin Mark Anstee, Vincent Wai‐Sun Wong, Frank Tacke, Manoli Vourvahis, Douglas S Lee, Michael Charlton, Naim Alkhouri, Atsushi Nakajima et al. · 2022 · BMJ Open
10. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights
    Ioanna Aggeletopoulou, Efthymios P. Tsounis, Christos K Triantos · 2024 · International Journal of Molecular Sciences
11. Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease
    Serena Pelusi, Luca V. C. Valenti · 2018 · Liver International
12. A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
    Ping An, Guangyan Wei, Pinzhu Huang, Wenda Li, Xiaolong Qi, Yi Lin, Kahini A. Vaid, Jun Wang, Shucha Zhang, Yang Li et al. · 2020 · Liver International
13. Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project
    Sanyal, Arun J., Shankar, Sudha S., Calle, Roberto A., Samir, Anthony E., Sirlin, Claude B., Sherlock, Sarah P., Loomba, Rohit, Fowler, Kathryn J., Dehn, Clayton A., Heymann, Helen et al. · 2022 · Nature Medicine
14. Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD)
    Anika Nier, Yvonne Huber, Christian Labenz, Maurice Stephan Michel, Ina Bergheim, Jörn Markus Schattenberg · 2020 · Nutrients
15. Patterns and predictors of mortality and disease progression among patients with non‐alcoholic fatty liver disease
    Ali E. Canbay, Nandita Kachru, Jennifer Scarlet Haas, Jan‐Peter Sowa, Dominic Meise, Ahmet Burak Ozbay · 2020 · Alimentary Pharmacology & Therapeutics
16. Non‐alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey
    Joon Ho Moon, Bo Kyung Koo, Won Kyum Kim · 2021 · Journal of Cachexia Sarcopenia and Muscle
17. Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
    Man Wang, Lei Li, Yannan Xu, Juan Du, Changquan Ling · 2022 · Frontiers in Pharmacology
18. Future therapy for non‐alcoholic fatty liver disease
    Danny Issa, Vaishali A. Patel, Arun Jayant Sanyal · 2018 · Liver International
19. Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH
    M. De Rudder, C. Bouzin, M. Nachit, Heloïse Louvegny, Greetje Vande Velde, Y. Julé, I. Leclercq · 2019 · Laboratory Investigation
20. Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms
    Takahashi, Hirokazu, Kotani, Kazuhiko, Tanaka, Kenichi, Egucih, Yuichiro, Anzai, Keizo · 2018 · Frontiers in Endocrinology
21. Transient versus two-dimensional shear-wave elastography in a multistep strategy to detect advanced fibrosis in NAFLD
    Cassinotto, Christophe, Boursier, Jérome, Paisant, Anita, Guiu, Boris, Irles‐Depe, Marie, Canivet, Clémence, Aube, Christophe, de Ledinghen, Victor · 2021 · Hepatology
22. Non-Alcoholic Fatty Liver Disease and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Practical Issues
    Romain Itier, Maéva Guillaume, Jean‐Etienne Ricci, François Roubille, Nicolas Delarche, François Picard, Michel Galinier, Jerome G. Roncalli · 2021 · ESC Heart Failure
23. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study
    Jing Zeng, Li Qin, Qian Jin, Rui‐Xu Yang, Guang Ning, Qing Su, ZHEN KUN YANG, Jian‐Gao Fan · 2022 · Hepatobiliary & pancreatic diseases international
24. Diabetes as a risk factor for MASH progression
    Sofiya Gancheva, Michael Roden, Laurent Castéra · 2024 · Diabetes Research and Clinical Practice
25. Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation
    Elizabeth M. Brunt · 2017 · Hepatology Communications
26. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non‐alcoholic fatty liver disease from tertiary care centres
    Maéva Guillaume, Valerie Moal, Cyrielle Delabaudière, Floraine Zuberbuhler, Marie‐Angèle Robic, Adrien Lannes, Sophie Métivier, Frédéric Oberti, Pierre Gourdy, Isabelle Fouchard‐Hubert et al. · 2019 · Alimentary Pharmacology & Therapeutics
27. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage
    Michal Segal-Salto, Neta Barashi, Avi Katav, Vicktoria Edelshtein, Arnon Aharon, Sharon Hashmueli, Jacob George, Yaakov Maor, Massimo Pinzani, Dan Haberman et al. · 2020 · JHEP Reports
28. Relationship between NAFLD and Periodontal Disease from the View of Clinical and Basic Research, and Immunological Response
    Masahiro Hatasa, Sumiko Yoshida, Hirokazu Takahashi, Kenichi Tanaka, Yoshihito Kubotsu, Yujin Ohsugi, Takaharu Katagiri, Takanori Iwata, Sayaka Katagiri · 2021 · International Journal of Molecular Sciences
29. European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline
    Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, Marjo J. E. Campmans-Kuijpers, Vincenzo Cardinale, Irit Chermesh, Ahad Eshraghian, Haluk Tarık Kani, Wafaa Khannoussi, L. Lacaze et al. · 2022 · United European Gastroenterology Journal
30. Ceramides are fuel gauges on the drive to cardiometabolic disease
    Joseph L. Wilkerson, Sean M. Tatum, William L. Holland, Scott A. Summers · 2024 · Physiological Reviews
31. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations
    Marco A. Arrese, Francisco Barrera M., Nicolás Triantafilo, Juan Pablo Arab · 2019 · Expert Review of Gastroenterology & Hepatology
32. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
    L. McSweeney, M. Breckons, G. Fattakhova, Y. Oluboyede, L. Vale, L. Ternent, M. Balp, L. Doward, C. Brass, Fiona R. Beyer et al. · 2020 · JHEP Reports
33. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases
    Robert J. Wong, Nandita Kachru, Diane Martinez, Meghan Moynihan, Ahmet Burak Ozbay, Stuart C. Gordon · 2020 · Journal of Clinical Gastroenterology
34. Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease
    Sander Lefere, Ellen Dupont, Ann De Guchtenaere, Stéphanie Van Biervliet, Saskia Vande Velde, Xavier Verhelst, Lindsey Devisscher, Hans Van Vlierberghe, Anja M. Geerts, Ruth De Bruyne · 2021 · Clinical Gastroenterology and Hepatology
35. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
    Jonathan David Roth, Sanne Skovgård Veidal, Louise K. D. Fensholdt, Kristoffer T. G. Rigbolt, Romeo Papazyan, Jens Christian Nielsen, Michael Feigh, Niels Vrang, Mark A. Young, Jacob Jelsing et al. · 2019 · Scientific Reports
36. Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
    Cyrielle Caussy, Jen-Chieh Chuang, Andrew N. Billin, Tao Hu, Wang Ya, G. Mani Subramanian, C. Stephen Djedjos, Robert P. Myers, Edward A. Dennis, Rohit Seth Loomba · 2020 · Therapeutic Advances in Gastroenterology
37. Redefining fatty liver disease classification in 2020
    Luca V. C. Valenti, Serena Pelusi · 2020 · Liver International
38. Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system
    Kostrzewski, Tomasz, Snow, Sophie, Battle, Anya Lindström, Peel, Samantha, Ahmad, Zahida, Basak, Jayati, Surakala, Manasa, Bornot, Aurelie, Lindgren, Julia, Ryaboshapkina, Maria et al. · 2021 · Communications Biology
39. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease
    Hagström, Hannes, Kechagias, Stergios, Ekstedt, Mattias · 2022 · Journal of Internal Medicine
40. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates
    Philippe Garteiser, Laurent Castéra, Muriel Coupaye, Sabrina Doblas, Daniela Calabrese, Marco Dioguardi Burgio, Séverine Ledoux, Pierre Bédossa, Marina Esposito‐Farèse, Simon Msika et al. · 2021 · JHEP Reports
41. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis
    Yong‐Yu Yang, Li Huitong Xie, Ning‐Ping Zhang, Da Zhou, Taotao Liu, Jian Huang Wu · 2022 · Acta Pharmacologica Sinica
42. MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
    Michael P. Cooreman, Luisa Vonghia, Sven Francque · 2024 · Diabetes Research and Clinical Practice
43. The hedgehog pathway in nonalcoholic fatty liver disease
    Mariana Verdelho Machado, Anna Mae Diehl · 2018 · Critical Reviews in Biochemistry and Molecular Biology
44. NASH: The Emerging Most Common Form of Chronic Liver Disease.
    Meron Tesfay, William Goldkamp, Brent A. Neuschwander‐Tetri · 2018 · Europe PMC (PubMed Central)
45. Effects of obesity on cholesterol metabolism and its implications for healthy ageing
    Mark T. Mc Auley · 2020 · Nutrition Research Reviews
46. Relationship between IL-8 Circulating Levels and TLR2 Hepatic Expression in Women with Morbid Obesity and Nonalcoholic Steatohepatitis
    Teresa Auguet, Laia Bertran, Jessica Binetti, Carmen Aguilar, Salomé Martínez, Fàtima Sabench, Jesús Miguel Lopez-Dupla, José Antonio Porras, David Riesco, Daniel Del Castillo et al. · 2020 · International Journal of Molecular Sciences
47. Meta-analysis: enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases
    Hinkson, Alexander, Lally, Hannah, Gibson, Hannah, Jones, Rebecca, Rowe, Ian A., Shinkins, Bethany, Parker, Richard · 2023 · Alimentary Pharmacology & Therapeutics
48. The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression
    Giorgia Benegiamo, Giacomo von Alvensleben, Sandra Rodríguez-López, Ludger J.E. Goeminne, Alexis Bachmann, Jean‐David Morel, Ellen Broeckx, Jing Ying Ma, Vinicius Carreira, Sameh A. Youssef et al. · 2023 · The Journal of Experimental Medicine
49. Fibrosis-4 Index Predicts Long-Term All-Cause, Cardiovascular and Liver-Related Mortality in the Adult Korean Population
    Young‐Gyun Seo, Stergios A. Pοlyzos, Kyung‐Hee Park, Christos Socrates Mantzoros · 2023 · Clinical Gastroenterology and Hepatology
50. Pediatric MASLD: current understanding and practical approach
    Anne-Sophie R Stroes, Miriam B. Vos, Marc Alexander Benninga, Bart G.P. Koot · 2024 · European Journal of Pediatrics
51. Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
    Toshifumi Tada, Takashi Kumada, Hidenori Toyoda, Kazuyuki Mizuno, Yasuhiro Sone, Tomoyuki Akita, Junko Tanaka · 2017 · Hepatology Communications
52. Extracellular matrix components indicate remodelling activity in different fibrosis stages of human non‐alcoholic fatty liver disease
    Isabelle D Munsterman, Timothy James Kendall, Nawel Khelil, Madalina Oana Popa, Roger M. L. M. Lomme, Joost P.H. Drenth, Eric T.T.L. Tjwa · 2018 · Histopathology
53. Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
    Zobair M. Younossi, Maria Stepanova, Issah M. Younossi, Andrei Racila · 2019 · Clinical Gastroenterology and Hepatology
54. Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD
    Annelise M. Poss, Scott A. Summers · 2020 · Frontiers in Endocrinology
55. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis
    Kanokwan Pinyopornpanish, Wael A. Al-Yaman, Robert Sam Butler, William W. Carey, Arthur J. McCullough, Carlos Romero‐Marrero · 2021 · The American Journal of Gastroenterology
56. Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis
    Stefano Ciardullo, Cinzia Ballabeni, Roberto Trevisan, Gianluca Perseghin · 2022 · Biomolecules
57. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Ryan Malcolm Buchanan, Daniel James Cuthbertson, Julie Parkes, Simon DS Fraser, Paul J. Roderick · 2023 · BMC Medicine
58. A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-β signaling in hepatic stellate cells
    Nanaho Kasahara, Yukiko Imi, Reina Amano, Masakazu Shinohara, Kumiko Okada, Yusei Hosokawa, Makoto Imamori, Chiaki Tomimoto, Jun Kunisawa, Shigenobu Kishino et al. · 2023 · Scientific Reports
59. Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Takeshi Okanoue, Toshihide Shima, Yasuhide Mitsumoto, Atsushi Umemura, Kanji Yamaguchi, Yoshito Itoh, Masato Yoneda, Atsushi Nakajima, Eishiro Mizukoshi, Shuichi Kaneko et al. · 2021 · Hepatology Research
60. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD
    Canivet, Clémence M., Costentin, Charlotte, Irvine, Katharina M., Delamarre, Adèle, Lannes, Adrien, Sturm, Nathalie, Oberti, Frederic, Patel, Preya J., Decaens, Thomas, Irles‐Depé, Marie et al. · 2023 · Hepatology
61. A WISP1 antibody inhibits MRTF signaling to prevent the progression of established liver fibrosis
    Ying Xi, Ryan LaCanna, Elsa-Noah N’Diaye, Sarah Gierke, Hsiao‐Yen Ma, Patrick Caplazi, Meredith S. Sagolla, Zhiyu Huang, Laura Lucio, Alexander Arlantico et al. · 2022 · Cell Metabolism
62. Nonalcoholic Fatty Liver Disease
    Scott D. Isaacs · 2022 · Endocrinology and Metabolism Clinics of North America
63. Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
    Piero Portincasa, György Baffy · 2024 · European Journal of Internal Medicine
64. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD)
    Michael Patrick Johnston, Janisha A. Patel, Christopher D. Byrne · 2020 · Current Pharmaceutical Design
65. Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice
    Maria Guarino, Pavitra Kumar, Andrea Felser, Luigi Terracciano, Sergi Guixé‐Muntet, Bostjan Humar, Michelangelo Foti, Jean‐Marc Nuoffer, Marie V. St–Pierre, Jean‐François Dufour · 2020 · Cancers
66. Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice
    Koop, Anja Christina, Thiele, Nina Doreen, Steins, David, Michaëlsson, Erik, Wehmeyer, Malte, Scheja, Ludger, Steglich, Babett, Huber, Samuel, Schulze zur Wiesch, Julian, Lohse, Ansgar W. et al. · 2020 · Hepatology Communications
67. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology
    Amin, Neeta B., Saxena, Aditi R., Somayaji, Veena, Dullea, Robert · 2023 · Clinical Therapeutics
68. Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
    Robert F. Schwabe, Frank Tacke, Atsushi Sugimoto, Scott L. Friedman · 2025 · JHEP Reports
69. Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities
    Wojciech Trzépizur, Jérôme Boursier, Marc Le Vaillant, Pierre‐Henri Ducluzeau, Severine G. Dubois, Samir Henni, Pierre Abraham, Christophe Aubé, Paul Calès, Frédéric Gagnadoux · 2018 · European Respiratory Journal
70. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease
    Krisztina Szántó, Jiawei Li, Paúl Cordero, Jude A. Oben · 2019 · Diabetes Metabolic Syndrome and Obesity
71. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease
    José Tadeu Stefano, Laura Vilar Guedes, Arthur Alencar Arrais de Souza, Denise Siqueira Vanni, Venâncio Avancini Ferreira Alves, Flair José Carrilho, Álvaro Largura, Marco A. Arrese, Claudia Pinto Marques Souza de Oliveira · 2020 · Annals of Hepatology
72. Multiparametric US for Identifying Patients with High-Risk NASH: A Derivation and Validation Study
    Katsutoshi Sugimoto, Dong Ho Lee, Jae Young Lee, Su Jong Yu, Fuminori Moriyasu, Kentaro Sakamaki, Hisashi Oshiro, Hiroshi Takahashi, Tatsuya Kakegawa, Yusuke Tomita et al. · 2021 · Radiology
73. Review Article: <scp>GLP</scp> ‐1 Receptor Agonists and Glucagon/ <scp>GIP</scp> / <scp>GLP</scp> ‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in <scp>MASLD</scp>
    Zafer, Maryam, Tavaglione, Federica, Romero‐Gómez, Manuel, Loomba, Rohit · 2025 · Alimentary Pharmacology &amp; Therapeutics
74. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges
    Lefere, Sander, Devisscher, Lindsey, Tacke, Frank · 2020 · Expert Opinion on Investigational Drugs
75. Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver
    Raffaella Maria Gadaleta, Antonio Moschetta · 2021 · Journal of Hepatology
76. The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
    Yasser Mahrous Fouad, Gamal Esmat, Reda Elwakil, Serag Zakaria, Ayman Yosry, Imam A. Waked, Maissa El-Razky, Wahid H. Doss, Magdy El‐Serafy, Ebraheem Mostafa et al. · 2022 · Saudi Journal of Gastroenterology
77. From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
    Ahmed Mohamed Samy, Mohamed A. Kandeil, Dina Sabry, A.A. Abdel-Ghany, Mohamed O. Mahmoud · 2024 · Heliyon
78. Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review
    Jake Peter Mann, George Yizhou Tang, Valério Nobili, Matthew James Armstrong · 2018 · Clinical Gastroenterology and Hepatology
79. Diet quality and its association with nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality
    Eric R. Yoo, Donghee Kim, Luis Miguel Vazquez‐Montesino, Jessica A. Escober, Andrew A. Li, Sean P. Tighe, Christopher T. Fernandes, George T. Cholankeril, Aijaz Ahmed · 2020 · Liver International
80. Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non‐invasive tests for the diagnosis of advanced liver fibrosis in patients with non‐alcoholic fatty liver disease
    Chika Inadomi, Hirokazu Takahashi, Yuji Ogawa, Satoshi Oeda, Kento Imajo, Yoshihito Kubotsu, Kenichi Tanaka, Takaomi Kessoku, Michiaki Okada, Hiroshi Isoda et al. · 2020 · Hepatology Research
81. Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness
    Chow, Jeremy Chak‐Lun, Wong, Grace Lai‐Hung, Chan, Anthony Wing‐Hung, Shu, Sally She‐Ting, Chan, Carmen Ka‐Man, Leung, Julie Ka‐Yu, Choi, Paul Cheung‐Lung, Chim, Angel Mei‐Ling, Chan, Henry Lik‐Yuen, Wong, Vincent Wai‐Sun · 2019 · Journal of Gastroenterology and Hepatology
82. Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications
    Katherine Martin, Anas Hatab, Varinder Singh Athwal, Elliot J. Jokl, Karen Piper Hanley · 2021 · Current Diabetes Reports
83. NASH in HIV
    Adriana Cervo, Mohamed Shengir, Keyur Patel, Giada Sebastiani · 2020 · Current HIV/AIDS Reports
84. Preparing for the NASH Epidemic: A Call to Action
    Fasiha Kanwal, Jay H. Shubrook, Zobair M. Younossi, Yamini Natarajan, Elisabetta Bugianesi, Mary Eugenia Rinella, Stephen A. Harrison, Christos Socrates Mantzoros, Kim M. Pfotenhauer, Samuel Klein et al. · 2021 · Diabetes Care
85. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease
    Wah‐Kheong Chan, Soek-Siam Tan, Siew-Pheng Chan, Yeong Yeh Lee, Hoi‐Poh Tee, Sanjiv Mahadeva, Khean‐Lee Goh, Anis Safura Ramli, Feisul Idzwan Mustapha, Nik Ritza Kosai et al. · 2022 · Journal of Gastroenterology and Hepatology
86. Histological assessment based on liver biopsy: the value and challenges in NASH drug development
    Xiaofei Tong, Qianyi Wang, Xinyan Zhao, Yameng Sun, Xiaoning Wu, Liling Yang, Zhengzhao Lu, Xiaojuan Ou, Jidong Jia, Hong You · 2022 · Acta Pharmacologica Sinica
87. Novel Therapeutic Approaches to Liver Fibrosis Based on Targeting Oxidative Stress
    Ana Blas‐García, Nadezda Apostolova · 2023 · Antioxidants
88. Pharmaco‐Economic Assessment of Screening Strategies for High‐Risk MASLD in Primary Care
    Zobair M. Younossi, James M. Paik, Linda L Henry, Maria Stepanova, Fatema Nader · 2024 · Liver International
89. Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis
    Vincent Wai‐Sun Wong, Ashwani Kumar Singal · 2019 · Translational Gastroenterology and Hepatology
90. Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexican‐American Population of South Texas
    Suet‐Ying Kwan, Jingjing Jiao, Jonathan Qi, Ying Wang, Peng Wei, Joseph B. McCormick, Susan P. Fisher‐Hoch, Laura Beretta · 2020 · Hepatology Communications
91. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees
    Kenichiro Murayama, Michiaki Okada, Kenichi Tanaka, Chika Inadomi, Wataru Yoshioka, Yoshihito Kubotsu, Tomomi Yada, Hiroshi Isoda, Takuya Kuwashiro, Satoshi Oeda et al. · 2021 · Diagnostics
92. Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
    Saleh A. Alqahtani, Pegah Golabi, James M. Paik, Brian P Lam, Amir H. Moazzez, Hazem A. Elariny, Zachary D Goodman, Zobair M. Younossi · 2021 · Obesity Surgery
93. Natural History of NAFLD
    Raluca Pais, Thomas Maurel · 2021 · Journal of Clinical Medicine
94. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease
    Anne‐Marieke van Dijk, Yasaman Vali, Anne Linde Mak, Jenny Lee, Maarten E. Tushuizen, Mohammad Hadi Zafarmand, Quentin Mark Anstee, M. Julia Brosnan, Max Nieuwdorp, Patrick M. Bossuyt et al. · 2021 · Journal of Clinical Medicine
95. Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease
    A‐Na Liu, Cuifang Xu, Ya‐Ru Liu, Dan‐Qin Sun, Ling Jiang, Liang‐Jie Tang, Pei‐Wu Zhu, Sui‐Dan Chen, Wen‐Yue Liu, Xiao‐Dong Wang et al. · 2023 · Alimentary Pharmacology & Therapeutics
96. Practical guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
    Stephan C. Bischoff, Johann Ockenga, Ahad Eshraghian, Rocco Barazzoni, Luca Busetto, Marjo J. E. Campmans-Kuijpers, Vincenzo Cardinale, Irit Chermesh, Haluk Tarık Kani, Wafaa Khannoussi et al. · 2023 · Clinical Nutrition
97. Liver biopsy evaluation in MASH drug development: Think thrice, act wise
    Stephen A. Harrison, Julie Dubourg · 2024 · Journal of Hepatology
98. Simple Scores of Fibrosis and Mortality in Patients with NAFLD: A Systematic Review with Meta-Analysis
    Federico Salomone, Agnieszka Micek, Justyna Godos · 2018 · Journal of Clinical Medicine
99. A PDGFRβ-based score predicts significant liver fibrosis in patients with chronic alcohol abuse, NAFLD and viral liver disease
    Joeri Lambrecht, Stefaan Verhulst, Inge Mannaerts, Jan‐Peter Sowa, Jan Best, Ali E. Canbay, Hendrik Reynaert, Leo A. van Grunsven · 2019 · EBioMedicine
100. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease
     Joeri Lambrecht, Frank Tacke · 2021 · Frontiers in Immunology